P373: Effect of risankizumab on improved and sustained quality of life in patients with moderate to severe Crohn’s disease: Phase 2 trial results
ECCO '19 Copenhagen
2019
P374: Effects of subcutaneous vedolizumab on health-related quality of life and work productivity in patients with ulcerative colitis: results from the Phase 3 VISIBLE 1 trial
ECCO '19 Copenhagen
2019
P375: Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multi-centre case series
ECCO '19 Copenhagen
2019
P376: Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn’s disease: results from the Phase 3b VERSIFY trial
ECCO '19 Copenhagen
2019
P377: Clinical strategies based on patient-reported outcomes and physicians’ preferences to monitor biological therapy in inflammatory bowel disease
ECCO '19 Copenhagen
2019
P378: Changes in Simplified Endoscopic Score for Crohn’s disease (SES-CD) during a 16-week induction treatment with upadacitinib: analysis of the randomised controlled CELEST study
ECCO '19 Copenhagen
2019
P379: Comparison of real-world treatment outcomes with infliximab vs. vedolizumab in biologic-naïve patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P380: A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis
ECCO '19 Copenhagen
2019
P381: Infliximab induction regimes in steroid refractory acute severe colitis: a multi-centre retrospective cohort study with propensity score analysis
ECCO '19 Copenhagen
2019
P382: Combination therapy with TNF-inhibitors and immunomodulators are associated with shorter duration to first serious infection: the DEVELOP experience
ECCO '19 Copenhagen
2019
P383: One-year experience with ustekinumab in therapy-refractory or -intolerant patients with ulcerative colitis
ECCO '19 Copenhagen
2019
P384: High incidence of hyperglycaemia in steroid treated hospitalised inflammatory bowel disease (IBD) patients and its risk factors identified by machine learning methods
ECCO '19 Copenhagen
2019
P385: TREM1, the first anti-TNF specific biomarker guiding therapeutic decision
ECCO '19 Copenhagen
2019
P386: Association of Infliximab trough levels and perianal disease activity in Crohn’s disease
ECCO '19 Copenhagen
2019
P387: Efficacy of combination therapy of fresh faecal microbiota transplantation and triple-antibiotic therapy for ulcerative colitis
ECCO '19 Copenhagen
2019
P388: Analysis of the impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis programme
ECCO '19 Copenhagen
2019
P389: Systematic review and meta-analysis of risk factors for recurrent primary sclerosing cholangitis
ECCO '19 Copenhagen
2019
P390: The impact of anti-TNF therapy in adjuvant setting on postoperative recurrence patterns over decades in complicated Crohn’s disease
ECCO '19 Copenhagen
2019